Browsing by Author Macfarlane, C

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue DateViews
 
Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
Proceeding/Conference:Journal of Hepatology
Yuen, RMFChen, CYLiu, CJJeng, RWJElkhashab, MCoffin, CKim, WGreenbloom, SRamji, ALim, YSKim, YJFung, SKim, DJJang, JWLee, KSAfdhal, NIyer, RMacfarlane, CJackson, KLocarnini, SChan, H
2019
54
 
Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
Proceeding/Conference:Journal of Hepatology
Yuen, RMFElkashab, MChen, CYCoffin, CFung, SGreenbloom, SJang, JWJeng, RWJKim, DJKim, YJKim, WLee, KSLim, YSRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NChan, H
2018
46
 
Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Walsh, RHammond, RJackson, KEdwards, EMacfarlane, CIyer, RYuen, RMFChan, HAfdhal, NLocarnini, S
2018
36
 
Inarigivir demonstrates potent dose dependent anti-viral activity in HBV treatment-naive patients: role of HBeAg status and baseline HBsAg in anti-viral response
Proceeding/Conference:Hepatology
Yuen, RMFElkhashab, MChen, CYChen, YFCoffin, CSFung, SKGreenbloom, SJang, JWJeng, WJKim, DJKim, YJKim, WLee, KSLim, YSLiu, CJRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NHChan, HLYACHIEVE STUDY Investigators,
2018
28
 
Inarigivir: a novel RIG-I agonist for chronic hepatitis B
Proceeding/Conference:Hepatology International
Macfarlane, CLocarnini, SJackson, KWalsh, REdwards, RHammond, RCoffin, CElkhashab, MGreenbloom, SRamji, AChan, HLYAfdhal, WKim, NAfdhal, NYuen, RMFWong, DKHLyer, R
2018
77
 
Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial
Proceeding/Conference:Hepatology
Locarnini, SWong, DKHJackson, KWalsh, REdwards, RHammond, RMacfarlane, CIyer, RPAfdhal, NHYuen, RMF
2017
32
 
SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naive, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial
Proceeding/Conference:Hepatology
Yuen, RMFCoffin, CSElkhashab, MGreenbloom, SRamji, AChan, HLYIyer, RPLocarnini, SMacfarlane, CAfdhal, NHKim, W
2017
44
Showing results 1 to 7 of 7